Form 8-K HALOZYME THERAPEUTICS For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
August 8, 2018 6:59 AM EDTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform rating.
Analsyt Do Kim commented, "We raise our target to $21 from $19, as our probability of success for PEGPH20 in pancreatic cancer increases to 70% from 65%, following positive... More
